Can Pregnant Women Take Phenylephrine?

Oral phenylephrine, the decongestant found in many over-the-counter cold and sinus products, is generally not recommended during pregnancy, particularly in the first trimester. The concern centers on its vasoconstricting properties, which can narrow blood vessels and have been linked in epidemiological studies to a small number of birth defects. Complicating the picture further, the FDA has raised serious doubts about whether oral phenylephrine even works as a decongestant at standard doses. For a pregnant person dealing with a stuffy nose, then, the calculus is especially unfavorable: a drug with potential fetal risks and questionable benefits.

What the Birth Defect Data Actually Shows

The most specific safety signal comes from a large case-control study using data from the National Birth Defects Prevention Study, which found an association between first-trimester phenylephrine use and endocardial cushion defects, a type of heart malformation. The odds ratio was 8.0, meaning exposed pregnancies were roughly eight times as likely to produce this defect compared to unexposed pregnancies, though the absolute number of affected cases was small (four exposed cases).¹ A broader clinical review of rhinitis treatment in pregnancy also noted that oral decongestants as a class have been associated with cardiac, ear, gut, and limb abnormalities, and recommended against their use in the first trimester.²

These findings come with important caveats. Case-control studies rely on mothers recalling what they took during early pregnancy, which introduces recall bias. The number of exposed cases in the phenylephrine-heart defect association was very small, so the confidence interval was wide. And the same large study failed to confirm several other previously hypothesized links between decongestants and birth defects.³ So the evidence is not overwhelming, but it points in a worrying enough direction that most clinical guidance errs on the side of caution, especially during the first trimester when organs are forming.

One related concern worth noting: a study specifically examining whether vasoconstrictive decongestants contribute to gastroschisis, an abdominal wall defect, found no meaningful association. The odds ratio was 1.0, which means essentially no increased risk.⁴ Not every feared association has panned out, but the cardiac defect signal has been enough to keep phenylephrine on the “avoid if possible” list for pregnancy.

The Efficacy Problem Makes the Risk Harder to Justify

Even setting pregnancy aside, oral phenylephrine has a credibility problem. The drug is heavily metabolized before it reaches your bloodstream. Early pharmacokinetic work established that while phenylephrine is well absorbed from the gut, it undergoes extensive first-pass metabolism in the liver and intestinal wall, with only about 38% of the dose reaching circulation as active drug, and the fraction of free (unconjugated) phenylephrine after an oral dose was measured at just 2.6% of the dose compared to 16% after intravenous administration.⁵ A more recent pharmacokinetic study of 10, 20, and 30 mg oral doses confirmed that plasma concentrations peak within about 30 minutes but remain extremely low, in the picogram-per-milliliter range.⁶

This pharmacokinetic reality is the reason the FDA convened an advisory committee that voted unanimously that oral phenylephrine, at the standard 10 mg dose sold in most products, is not effective as a nasal decongestant. A systematic review of the clinical trial evidence echoed this conclusion and noted the broader regulatory concern about recommending medications with dubious efficacy.⁷ For a pregnant person weighing the risks and benefits, the math is bleak: you are taking on a potential, if unproven, risk for what is likely a placebo-level benefit.

The Confusing Part About Phenylephrine in Labor and Delivery

If you search for phenylephrine and pregnancy, you will run into a seemingly contradictory body of literature where phenylephrine is described as the preferred drug for pregnant patients. This refers to intravenous phenylephrine used during cesarean deliveries, and it is a completely different clinical situation from taking an oral cold tablet at home.

When a person receives spinal anesthesia for a cesarean section, their blood pressure often drops suddenly. Anesthesiologists need a vasopressor to bring it back up quickly. For years, ephedrine was the go-to choice. But research over the past two decades has reversed that preference. Phenylephrine given by IV infusion during cesarean delivery now maintains maternal blood pressure more reliably than ephedrine and leads to better neonatal outcomes, with significantly lower rates of fetal acidosis.⁸ A randomized trial comparing prophylactic phenylephrine infusion with ephedrine and a control group found that neonatal acidosis occurred in about 6% of the phenylephrine group versus 30% with ephedrine.⁹ A meta-analysis confirmed that phenylephrine is associated with lower fetal acidosis rates, higher umbilical cord pH values, and less base excess in elective surgery.¹⁰

Phenylephrine is now considered the vasopressor of choice for managing spinal hypotension during cesarean delivery, though it can cause maternal bradycardia (a slowed heart rate) as a side effect.¹¹ The point for any pregnant person reading about phenylephrine safety is that these hospital-based IV studies do not tell you anything about whether it is safe to take an oral decongestant tablet at home in the first trimester. The dose, the route, the timing in pregnancy, and the clinical context are all different.

What IV Phenylephrine Does to Placental Blood Flow

Research into how IV phenylephrine affects the placenta and fetus reveals a nuanced picture that helps explain why it works well for cesareans but still raises concerns about blood vessel constriction more broadly. Imaging studies using BOLD MRI in animal models showed that phenylephrine caused roughly a 50% reduction in blood flow signals in the placenta, fetal heart, and fetal liver. The fetal brain, however, was spared from this reduction, a protective mechanism known as brain sparing where the fetus redirects blood flow to its most critical organ.¹²

Additional animal research found that phenylephrine impaired fetal left ventricular function, reducing cardiac output and ejection force in fetal sheep.¹³ Studies measuring uterine and placental artery resistance during phenylephrine infusion in human pregnancies have shown mixed results: one study observed a significant increase in vascular resistance in uterine and placental arteries, while another found no significant difference from baseline.¹⁴ In the cesarean setting these effects are transient, monitored, and offset by the benefit of keeping maternal blood pressure stable. But they illustrate why phenylephrine’s vasoconstricting action is a legitimate concern for the developing fetus, particularly during prolonged or repeated oral exposure in early pregnancy.

Why Your Nose Is Stuffy in the First Place

Pregnancy rhinitis, the persistent nasal congestion that develops during pregnancy without any infection or allergy trigger, affects a significant number of pregnant people and frequently goes undiagnosed or gets mistakenly attributed to a cold or seasonal allergies.¹⁵ It is driven by the hormonal changes of pregnancy: rising estrogen, progesterone, and placental growth factors increase blood flow to the nasal mucosa, cause swelling of the tissues lining the nose, and ramp up mucus production. The result is a stuffy nose that can last weeks or months, interfere with sleep, and make an already uncomfortable pregnancy worse.

Understanding that pregnancy rhinitis is hormonal rather than infectious is useful because it changes which treatments make sense. Antibiotics are pointless. Antihistamines help only if there is an allergic component. And decongestants, even if they worked, would be fighting a hormonally driven process that will resolve after delivery. This is why clinical guidance tends to emphasize non-drug approaches first and reserve medication for cases where congestion is severe enough to compromise sleep or breathing.

What You Can Actually Use Instead

The first-line approach for nasal congestion in pregnancy is non-pharmacological. Saline nasal irrigation, using either a squeeze bottle or a neti pot with sterile water, reduces symptoms including stuffiness, runny nose, itching, and sneezing.¹⁶ Adhesive nasal strips and internal nasal dilators can improve the sensation of airflow through the nose without introducing any medication into the body.¹⁷ Moderate exercise also helps: physical activity naturally constricts nasal blood vessels through sympathetic nervous system activation, providing temporary relief from congestion. One clinical guide specifically emphasized that a combination of environmental modification, saline rinses, exercise, and nasal strips can prevent congestion from escalating into a more serious problem.¹⁸

When non-drug measures are not enough, intranasal corticosteroid sprays are considered the most effective medication for nasal congestion and have not been associated with increased congenital malformations. Because they deliver medication directly to the nasal lining with very little absorbed into the bloodstream, they are generally recommended as first-line pharmacotherapy over oral antihistamines, decongestants, and mast cell stabilizers during pregnancy.¹⁹ Your provider may recommend budesonide nasal spray specifically, as it has the most pregnancy safety data of the available intranasal steroids.

For allergic symptoms like sneezing and itching on top of congestion, older antihistamines like chlorpheniramine have the longest safety track record in pregnancy. Among newer antihistamines, loratadine has the most human pregnancy data, with studies covering over 2,000 exposed women showing no apparent increase in birth defects.²⁰ Cetirizine has also not been linked to birth defects, though its safety record in pregnancy is somewhat shorter.²¹

Watch Out for Combination Products

One of the more practical hazards is accidentally taking phenylephrine without realizing it. Many over-the-counter cold, flu, and sinus remedies are combination products that bundle a pain reliever, an antihistamine, a cough suppressant, and a decongestant into a single pill or liquid. Some contain as many as five active ingredients.²² The product name on the box often gives no clear indication that a decongestant is included. Words like “multi-symptom,” “severe,” or “sinus” in a product name are clues that a decongestant may be part of the formula, but the only reliable way to check is to read the active ingredients panel on the back.

If you are pregnant and picking up a cold remedy, look for phenylephrine HCl in the drug facts. It is commonly listed at 5 mg or 10 mg per dose. Also watch for pseudoephedrine, the other common oral decongestant, which carries its own set of pregnancy concerns. Single-ingredient products are easier to evaluate: a box containing only acetaminophen for headache, or only dextromethorphan for cough, lets you know exactly what you are taking. Your pharmacist can help sort through the options if the labels are confusing, and consulting with one before buying any OTC medication during pregnancy is a habit worth forming.

The Nasal Spray Decongestant Trap

Topical nasal decongestant sprays like oxymetazoline (Afrin) deliver medication directly to the nasal lining, and because very little enters the bloodstream, they are sometimes considered a safer short-term option than oral decongestants during pregnancy. But they introduce a different problem: rebound congestion. Using a nasal decongestant spray for more than three consecutive days can cause the nasal tissues to swell even worse once the spray wears off, a condition called rhinitis medicamentosa. This creates a cycle where you need the spray just to breathe normally, and your congestion becomes worse than it was before you started.

Clinical guidance specifically warns pregnant patients to avoid nasal spray decongestants because of this rebound risk.²³ A person dealing with weeks or months of pregnancy rhinitis is exactly the type of patient who would be tempted to keep using a spray beyond the safe window, and once rebound congestion sets in, the condition escalates and becomes harder to manage without medication. Saline sprays, by contrast, carry no rebound risk and can be used as often as needed.

Timing Matters Within Pregnancy

The first trimester is the period of greatest concern for any drug with teratogenic potential, because this is when the major organs are forming. The heart, for example, is largely structured by about eight weeks of gestation, which is why the endocardial cushion defect signal associated with phenylephrine is a first-trimester exposure concern.²⁴ After the first trimester, the risk profile shifts: the major structures are already formed, so the concern is less about structural birth defects and more about effects on fetal growth and placental function.

Some providers are more willing to consider short-term oral decongestant use in the second or third trimester when congestion is severe and non-drug approaches have failed. A review of common cold treatments during pregnancy noted that the available evidence for most OTC cold ingredients suggests no increased risk with short-term use, though it emphasized that pregnant women should avoid taking medications they do not need.²⁵ Even later in pregnancy, the vasoconstricting action of phenylephrine could theoretically reduce blood flow to the placenta, so the decision is best made with a provider who knows your specific situation.

If You Already Took Some Before You Knew

Many people discover they are pregnant several weeks into the first trimester, and quite a few will have taken a cold or sinus product containing phenylephrine before they knew. The evidence linking oral phenylephrine to birth defects involves small numbers of cases and modest absolute risk even in the worst-case scenario. The endocardial cushion defect association, while statistically significant, was based on four exposed cases out of a large study population.²⁶ Endocardial cushion defects are rare to begin with. An eight-fold increase in a rare event is still a rare event.

This is not meant to minimize the concern, but to put it in perspective. A single dose or even a few days of phenylephrine early in pregnancy is not grounds for panic. It is worth mentioning to your prenatal care provider so they can note it in your chart and, if appropriate, check fetal heart anatomy on a routine anatomy scan. What you should not do is continue using the product once you know you are pregnant, because every additional exposure is an unnecessary roll of the dice for a drug that probably is not helping your congestion anyway.